Adolescent anxiety disorders Mental and Behavioural Disorders Anxiety disorder, unspecified
Conditions
Interventions
Participants are invited to join the study after their initial assessment at the clinic. 48 adolescents whose primary presenting problem is an anxiety disorder will be randomised to receive either thi
Sponsors
University of Reading
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Young people (aged 11-17.5 years at intake) whose primary presenting disorder is a DSM-5 diagnosis of an anxiety disorder 2. If young people have been prescribed psychotropic medication the dosage must have been stable for two months
Exclusion criteria
Exclusion criteria: 1. Young people with co-morbid conditions that are likely to interfere with treatment delivery, to include an established autistic spectrum disorder or learning disabilities, suicidal intent or recurrent or potentially life-limiting self-harm (i.e., current frequency of at least once per week or self-harm that requires medical attention) 2. Young people with a primary presenting disorder other than an anxiety disorder (including a DSM-V diagnosis of major depressive disorder (MDD)) 3. Young people identified by social services as currently ‘at risk’ due to child protection concerns
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of a definitive RCT on the basis of acceptability of the treatments and trial procedures measured at the end of treatment and after the 3 month follow-up session. Treatment and trial acceptability is assessed through examination of recruitment rates, rate of treatment drop out, and retention to research assessments post treatment and at 3 month follow up (and also a self-report measure, the Commission for Health Improvement Experience of Service Questionnaire (ESQ) completed by parent and young person post treatment and at 3-month follow up). Feasibility will also be informed by evidence that ACTA can be delivered so that it is clearly distinct from the Chilled Group Therapy, with high levels of fidelity by practitioners and credibility with patients in both arms. This will be measured using a treatment integrity scale to compare video tapes of a sample of the sessions, and also on a session by session basis using therapy content checklists completed by clinicians and Session Rating Scales (SRS) completed by the young person. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Anxiety symptoms, measured using Revised Children Anxiety and Depression Scales (RCADs, child and parent report), administered at baseline, prior to each treatment session, at the end of treatment and at the 3 month follow up session 2. The extent to which anxiety interferes in the adolescent’s life, measured using the Child Anxiety and Impact Scale (CAIS, child and parent report) at baseline, post treatment and after 3 months and supplemented by Adolescent Sleep Questionnaire (child report) administered at these time points to probe participants' sleep patterns 3. Diagnostic status, measured using a full diagnostic assessment which will take place prior to treatment and after the 3-month follow up. Each of these will comprise two diagnostic interviews (one with the parent/carer, one with the young person) where presence of an anxiety disorder will be determined by administering the Anxiety section of the Anxiety Disorders Interview Schedule (ADIS) and presence of a mood disorder will be determined by administering the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) 4. Overall functioning assessed using the Children’s Global Assessment Scale (CGAS), and changes to this will be measured using the Clinical Global Impression Scale – Improvement (CGI-I) 5. Health-related quality of life, measured using the EuroQol (Quality of Life) (EQ-5D, parent and child report) and the paediatric measure Child Health Utility (Paediatric Quality of Life) (CHU-9D, parent and child report) at baseline, post treatment and at 3-month follow up 6. Healthcare resource usage, measured by parent/care completion of a Client Services Receipt Inventory (CSRI) at baseline, post treatment and at 3 month follow up using patient-health diaries to facilitate recall. Also, economic logs will be completed by Clinicians and Supervisors to measure time and resources spent on all aspects of the treatment | — |
Countries
England, United Kingdom
Contacts
Public ContactLucy Taylor
Outcome results
None listed